Actualités Saniona Ab - 0RQJ | Actions London Stock Exchange

Saniona AB’s Nomination Committee for the Annual General Meeting 2023

Saniona AB’s Nomination Committee for the Annual General Meeting 2023 PRESS RELEASE November 25, 2022 Saniona (OMX: SANION), a clinical...

Saniona publishes its interim report for the third quarter of 2022

Saniona publishes its interim report for the third quarter of 2022 Three Months Ended September 30, 2022 (2021)Nine Months Ended September...

Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies

Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies PRESS RELEASE November 3, 2022 SAN903 has...

Saniona extends runway and amends loan agreement with Formue Nord

Saniona extends runway and amends loan agreement with Formue Nord PRESS RELEASE September 30, 2022 Saniona (OMX: SANION), a clinical stage...

Saniona publishes its interim report for the second quarter of 2022

Saniona publishes its interim report for the second quarter of 2022 Three Months Ended June 30, 2022 (2021)Six Months Ended June 30, 2022...

Bulletin from the Saniona AB extraordinary general meeting on August 18, 2022

Bulletin from the Saniona AB extraordinary general meeting on August 18, 2022 PRESS RELEASE August 18, 2022 Today, on August 18, 2022, an...

Saniona progresses its Kv7 epilepsy program into Lead Optimization

Saniona progresses its Kv7 epilepsy program into Lead Optimization PRESS RELEASE August 16, 2022 Saniona (OMX: SANION), a clinical stage...

Saniona provides update on outstanding option programs

Saniona provides update on outstanding option programs PRESS RELEASE August 5, 2022 Saniona (OMX: SANION), a clinical stage...

Notice of extraordinary general meeting in Saniona AB

Notice of extraordinary general meeting in Saniona AB PRESS RELEASE 15 July 2022 The English text is an unofficial translation. In case of...

Saniona CEO Thomas Feldthus and board member Carl Johan Sundberg purchase Saniona shares in the open market

Saniona CEO Thomas Feldthus and board member Carl Johan Sundberg purchase Saniona shares in the open market PRESS RELEASE July 6, 2022...

Saniona reports positive top line results from the SAN711 Phase 1 Clinical Trial

Saniona reports positive top line results from the SAN711 Phase 1 Clinical Trial PRESS RELEASE June 30, 2022 Saniona (OMX: SANION), a...

Saniona’s preclinical candidate SAN903 shows robust dampening of fibrosis in Chronic Kidney Disease model

Saniona’s preclinical candidate SAN903 shows robust dampening of fibrosis in Chronic Kidney Disease model PRESS RELEASE June 24, 2022...

Bulletin from the Saniona AB annual shareholders’ meeting on May 25, 2022

Bulletin from the Saniona AB annual shareholders’ meeting on May 25, 2022 PRESS RELEASE May 25, 2022 Today, on May 25, 2022, the annual...

Saniona publishes its interim report for the first quarter of 2022

Saniona publishes its interim report for the first quarter of 2022 Q1 2022 (Q1 2021) Revenue was SEK 6.6 M (3.4 M)Operating loss was SEK...

Saniona´s Clinical Trial in Hypothalamic Obesity Published in Scientific Journal

Saniona´s Clinical Trial in Hypothalamic Obesity Published in Scientific Journal PRESS RELEASE May 23, 2022 Saniona (OMX: SANION), a...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Saniona Ab (0RQJ)

Outils de qualité professionnelle, pour des investisseurs individuels.

0RQJ Actualités

Saniona AB’s Nomination Committee for the Annual General Meeting 2023

Saniona publishes its interim report for the third quarter of 2022

Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies

Saniona extends runway and amends loan agreement with Formue Nord

Saniona publishes its interim report for the second quarter of 2022

Bulletin from the Saniona AB extraordinary general meeting on August 18, 2022

Saniona progresses its Kv7 epilepsy program into Lead Optimization

Saniona provides update on outstanding option programs

Notice of extraordinary general meeting in Saniona AB

Saniona CEO Thomas Feldthus and board member Carl Johan Sundberg purchase Saniona shares in the open market

Saniona reports positive top line results from the SAN711 Phase 1 Clinical Trial

Saniona’s preclinical candidate SAN903 shows robust dampening of fibrosis in Chronic Kidney Disease model

Bulletin from the Saniona AB annual shareholders’ meeting on May 25, 2022

Saniona publishes its interim report for the first quarter of 2022

Saniona´s Clinical Trial in Hypothalamic Obesity Published in Scientific Journal

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Saniona Ab (0RQJ) Actualités

Saniona Ab (0RQJ)

Outils de qualité professionnelle, pour des investisseurs individuels.

0RQJ Actualités

Saniona AB’s Nomination Committee for the Annual General Meeting 2023

Saniona publishes its interim report for the third quarter of 2022

Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies

Saniona extends runway and amends loan agreement with Formue Nord

Saniona publishes its interim report for the second quarter of 2022

Bulletin from the Saniona AB extraordinary general meeting on August 18, 2022

Saniona progresses its Kv7 epilepsy program into Lead Optimization

Saniona provides update on outstanding option programs

Notice of extraordinary general meeting in Saniona AB

Saniona CEO Thomas Feldthus and board member Carl Johan Sundberg purchase Saniona shares in the open market

Saniona reports positive top line results from the SAN711 Phase 1 Clinical Trial

Saniona’s preclinical candidate SAN903 shows robust dampening of fibrosis in Chronic Kidney Disease model

Bulletin from the Saniona AB annual shareholders’ meeting on May 25, 2022

Saniona publishes its interim report for the first quarter of 2022

Saniona´s Clinical Trial in Hypothalamic Obesity Published in Scientific Journal

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application